Addiction is a striking behavioral state marked by compulsive drug use and inability to control use despite serious negative consequences. There has been a great deal of progress in recent years at the behavioral, systems neurobiologic, and molecular levels which has led to the idea that addiction is a disorder produced in an epigenetically vulnerable brain by repetitive or chronic exposure to strongly reinforcing drugs (Hyman, 1996) . While the precise steps involved in the progression from experimental or social drug use to addiction are not yet clear, the past decade has seen a great deal of progress on the neural pathways underlying addiction and the drug-induced adaptations in those pathways that might give rise to the addicted state (Hyman, 1996; Nestler, 1996; Self & Nestler, 1995) . In this brief review we discuss one set of particularly well-characterized drug-induced molecular adaptations that may play a role in addictionthose occurring in the striatum in response to acute and chronic psychostimulant administration.
CLINICAL MANIFESTATIONS
The psychostimulant drugs cocaine and amphetamine acutely produce euphoria, increased energy, motor activity or restlessness, and sympathetic arousal (e.g., increase in heart rate and blood pressure). With repeated doses, some effects of psychostimulants decrease (tolerance) while others increase (sensitization). In order to achieve euphoria, for example, chronic users may take psychostimulant doses that would be lethal to a drug-naive individual. In addition to exhibiting tolerance, chronic drug users may become ''dependent'' on the drug, i.e., upon drug cessation an adapted state of the brain is unmasked that produces withdrawal symptoms. It is likely that similar homeostatic responses to drug stimulation underlie the development of tolerance and dependence. The neural pathways in which particular drugs produce adaptations underlying dependence determine the drug-specific withdrawal symptoms. Adaptations in brain reward pathways are hypothesized to produce the depressionlike symptoms of anhedonia and dysphoria experienced by many individuals (and perhaps animal models) after cessation of psychostimulant use, the so-called motivational and emotional symptoms of withdrawal (Markou & Koob, 1991) . In contrast to the psychostimulants, withdrawal from ethanol and opiates involves not only motivational and emotional aspects, but also physical symptoms reflecting drug-induced adaptations in diverse pathways that regulate somatic, e.g., autonomic, function.
At the same time that they exhibit symptoms of tolerance and dependence, chronic psychostimulant users and animal models may exhibit manifestations of sensitization. For example, the motivational drive to use psychostimulants in human users may increase despite a decrease in the pleasure-due to tolerance or side effects-derived from the drug. Thus, there often develops a dissociation between ''wanting'' the drug and ''liking '' it (Robinson & Berridge, 1993) . Closely
